PL3656384T3 - Kombinacje zawierające pochodne 5-fenoksy-3h-pirymidyn-4-onu i ich zastosowanie do profilaktyki lub leczenia infekcji hiv - Google Patents

Kombinacje zawierające pochodne 5-fenoksy-3h-pirymidyn-4-onu i ich zastosowanie do profilaktyki lub leczenia infekcji hiv

Info

Publication number
PL3656384T3
PL3656384T3 PL19210167T PL19210167T PL3656384T3 PL 3656384 T3 PL3656384 T3 PL 3656384T3 PL 19210167 T PL19210167 T PL 19210167T PL 19210167 T PL19210167 T PL 19210167T PL 3656384 T3 PL3656384 T3 PL 3656384T3
Authority
PL
Poland
Prior art keywords
pyrimidin
prophylaxis
hiv
phenoxy
infection
Prior art date
Application number
PL19210167T
Other languages
English (en)
Inventor
Kenneth L. Arrington
Christopher Burgey
Robert Gilfillan
Yongxin Han
Mehul Patel
Chun Sing Li
Yaozong LI
Yunfu Luo
Jiayi Xu
Original Assignee
Merck Sharp & Dohme Corp.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme Corp. filed Critical Merck Sharp & Dohme Corp.
Publication of PL3656384T3 publication Critical patent/PL3656384T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/56—One oxygen atom and one sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Enzymes And Modification Thereof (AREA)
PL19210167T 2012-10-08 2013-10-07 Kombinacje zawierające pochodne 5-fenoksy-3h-pirymidyn-4-onu i ich zastosowanie do profilaktyki lub leczenia infekcji hiv PL3656384T3 (pl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN2012001358 2012-10-08
EP17191307.2A EP3295942B1 (en) 2012-10-08 2013-10-07 Combinations comprising 5-phenoxy-3h-pyrimidin-4-one derivatives and their use for the prophylaxis or treatment of infection by hiv
PCT/US2013/063612 WO2014058747A1 (en) 2012-10-08 2013-10-07 5-phenoxy-3h-pyrimidin-4-one derivatives and their use as hiv reverse transcriptase inhibitors
EP19210167.3A EP3656384B1 (en) 2012-10-08 2013-10-07 Combinations comprising 5-phenoxy-3h-pyrimidin-4-one derivatives and their use for the prophylaxis or treatment of infection by hiv
EP13776702.6A EP2903977B1 (en) 2012-10-08 2013-10-07 5-phenoxy-3h-pyrimidin-4-one derivatives and their use as hiv reverse transcriptase inhibitors

Publications (1)

Publication Number Publication Date
PL3656384T3 true PL3656384T3 (pl) 2022-04-04

Family

ID=49354986

Family Applications (3)

Application Number Title Priority Date Filing Date
PL13776702T PL2903977T3 (pl) 2012-10-08 2013-10-07 Pochodne 5-fenoksy-3h-pirymidyn-4-onu i ich zastosowanie jako inhibitorów odwrotnej transkryptazy hiv
PL19210167T PL3656384T3 (pl) 2012-10-08 2013-10-07 Kombinacje zawierające pochodne 5-fenoksy-3h-pirymidyn-4-onu i ich zastosowanie do profilaktyki lub leczenia infekcji hiv
PL17191307T PL3295942T3 (pl) 2012-10-08 2013-10-07 Kombinacje zawierające pochodne 5-fenoksy-3h-pirymidyn-4-onu i ich zastosowanie do profilaktyki lub leczenia infekcji hiv

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL13776702T PL2903977T3 (pl) 2012-10-08 2013-10-07 Pochodne 5-fenoksy-3h-pirymidyn-4-onu i ich zastosowanie jako inhibitorów odwrotnej transkryptazy hiv

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL17191307T PL3295942T3 (pl) 2012-10-08 2013-10-07 Kombinacje zawierające pochodne 5-fenoksy-3h-pirymidyn-4-onu i ich zastosowanie do profilaktyki lub leczenia infekcji hiv

Country Status (46)

Country Link
US (3) US9469634B2 (pl)
EP (3) EP3295942B1 (pl)
JP (2) JP5877281B2 (pl)
KR (1) KR101696128B1 (pl)
CN (1) CN104822670B (pl)
AP (1) AP2015008355A0 (pl)
AR (1) AR092876A1 (pl)
AU (1) AU2013329552B8 (pl)
BR (1) BR112015007742B8 (pl)
CA (1) CA2887312C (pl)
CL (1) CL2015000880A1 (pl)
CO (1) CO7350655A2 (pl)
CR (1) CR20150183A (pl)
CY (3) CY1119655T1 (pl)
DK (3) DK3656384T3 (pl)
DO (1) DOP2015000082A (pl)
EA (1) EA033436B1 (pl)
EC (1) ECSP15018618A (pl)
ES (3) ES2909190T3 (pl)
GE (1) GEP20186838B (pl)
GT (1) GT201500088A (pl)
HR (3) HRP20171819T1 (pl)
HU (3) HUE037231T2 (pl)
IL (1) IL238090B (pl)
JO (1) JO3470B1 (pl)
LT (3) LT3295942T (pl)
MA (1) MA37959A2 (pl)
MD (1) MD4625C1 (pl)
ME (1) ME02918B (pl)
MX (1) MX355040B (pl)
MY (1) MY192716A (pl)
NI (1) NI201500048A (pl)
NO (1) NO2903977T3 (pl)
NZ (1) NZ706729A (pl)
PE (1) PE20151787A1 (pl)
PH (1) PH12015500764B1 (pl)
PL (3) PL2903977T3 (pl)
PT (3) PT3656384T (pl)
RS (3) RS63112B1 (pl)
SG (1) SG11201502620UA (pl)
SI (3) SI2903977T1 (pl)
TN (1) TN2015000106A1 (pl)
TW (2) TWI598343B (pl)
UA (1) UA114006C2 (pl)
WO (1) WO2014058747A1 (pl)
ZA (1) ZA201503143B (pl)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012048113A2 (en) 2010-10-07 2012-04-12 The General Hospital Corporation Biomarkers of cancer
JO3470B1 (ar) 2012-10-08 2020-07-05 Merck Sharp & Dohme مشتقات 5- فينوكسي-3h-بيريميدين-4-أون واستخدامها كمثبطات ناسخ عكسي ل hiv
US9340799B2 (en) 2013-09-06 2016-05-17 President And Fellows Of Harvard College MRNA-sensing switchable gRNAs
US9322037B2 (en) 2013-09-06 2016-04-26 President And Fellows Of Harvard College Cas9-FokI fusion proteins and uses thereof
EP3046912A1 (de) 2013-09-16 2016-07-27 Bayer Pharma Aktiengesellschaft Disubstituierte trifluormethylpyrimidinone und ihre verwendung als ccr2 antagonisten
SI3125894T1 (sl) * 2014-04-01 2020-12-31 Merck Sharp & Dohme Corp. Predzdravila inhibitorjev reverzne transkriptaze HIV
EP3161159B1 (en) 2014-06-25 2020-08-05 The General Hospital Corporation Targeting human satellite ii (hsatii)
BR112017003745A2 (pt) 2014-08-29 2017-12-05 Tes Pharma S R L inibidores de semialdeído descarboxilase de ácido alfa-amino-beta-carboximucônico
FR3027901B1 (fr) * 2014-10-31 2018-03-16 Universite De Reims Champagne Ardenne Nouveaux procedes appartenant a la famille des pyridazinones.
US10350165B2 (en) * 2014-12-12 2019-07-16 Ojai Energetics Pbc Methods and systems for forming stable droplets
WO2017070632A2 (en) 2015-10-23 2017-04-27 President And Fellows Of Harvard College Nucleobase editors and uses thereof
WO2018027078A1 (en) 2016-08-03 2018-02-08 President And Fellows Of Harard College Adenosine nucleobase editors and uses thereof
AU2017308889B2 (en) 2016-08-09 2023-11-09 President And Fellows Of Harvard College Programmable Cas9-recombinase fusion proteins and uses thereof
WO2018039438A1 (en) 2016-08-24 2018-03-01 President And Fellows Of Harvard College Incorporation of unnatural amino acids into proteins using base editing
KR20240007715A (ko) 2016-10-14 2024-01-16 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 핵염기 에디터의 aav 전달
WO2018119359A1 (en) 2016-12-23 2018-06-28 President And Fellows Of Harvard College Editing of ccr5 receptor gene to protect against hiv infection
WO2018165504A1 (en) 2017-03-09 2018-09-13 President And Fellows Of Harvard College Suppression of pain by gene editing
KR20190123328A (ko) 2017-03-09 2019-10-31 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 암 백신
CN110914310A (zh) 2017-03-10 2020-03-24 哈佛大学的校长及成员们 胞嘧啶至鸟嘌呤碱基编辑器
IL306092A (en) 2017-03-23 2023-11-01 Harvard College Nucleic base editors that include nucleic acid programmable DNA binding proteins
US11560566B2 (en) 2017-05-12 2023-01-24 President And Fellows Of Harvard College Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation
EP3658573A1 (en) 2017-07-28 2020-06-03 President and Fellows of Harvard College Methods and compositions for evolving base editors using phage-assisted continuous evolution (pace)
EP3676376B1 (en) 2017-08-30 2025-01-15 President and Fellows of Harvard College High efficiency base editors comprising gam
US12435078B2 (en) 2017-09-18 2025-10-07 Gfb (Abc), Llc Pyridazinones and methods of use thereof
CA3082251A1 (en) 2017-10-16 2019-04-25 The Broad Institute, Inc. Uses of adenosine base editors
US12406749B2 (en) 2017-12-15 2025-09-02 The Broad Institute, Inc. Systems and methods for predicting repair outcomes in genetic engineering
EP4317972A3 (en) 2018-02-06 2024-03-13 The General Hospital Corporation Repeat rna as biomarkers of tumor immune response
BR112020022006A2 (pt) 2018-04-30 2021-01-26 Ribon Therapeutics Inc. piridazinonas como inibidores de parp7
WO2019226953A1 (en) 2018-05-23 2019-11-28 The Broad Institute, Inc. Base editors and uses thereof
EP3820495A4 (en) 2018-07-09 2022-07-20 The Broad Institute Inc. RNA-PROGRAMMABLE EPIGENETIC RNA MODIFIERS AND THEIR USES
LT3852533T (lt) 2018-09-18 2024-06-10 Gfb (Abc), Llc Piridazinonai ir jų naudojimo būdai
WO2020092453A1 (en) 2018-10-29 2020-05-07 The Broad Institute, Inc. Nucleobase editors comprising geocas9 and uses thereof
MX2021007382A (es) * 2018-12-18 2021-07-15 Merck Sharp & Dohme Llc Derivados de pirimidona como agentes citotoxicos selectivos contra celulas infectadas por vih.
US12351837B2 (en) 2019-01-23 2025-07-08 The Broad Institute, Inc. Supernegatively charged proteins and uses thereof
WO2020191241A1 (en) 2019-03-19 2020-09-24 The Broad Institute, Inc. Methods and compositions for editing nucleotide sequences
CA3136632A1 (en) 2019-04-11 2020-10-15 Goldfinch Bio, Inc. Spray-dried formulation of a pyridazinone trpc5 inhibitor
WO2020214842A1 (en) 2019-04-17 2020-10-22 The Broad Institute, Inc. Adenine base editors with reduced off-target effects
WO2020223229A1 (en) 2019-04-29 2020-11-05 Ribon Therapeutics, Inc. Solid forms of a parp7 inhibitor
AU2020279954B2 (en) * 2019-05-22 2025-11-13 Merck Sharp & Dohme Llc Pyridinone derivatives as selective cytotoxic agents against HIV infected cells
US20220259617A1 (en) 2019-06-13 2022-08-18 The General Hospital Corporation Engineered human-endogenous virus-like particles and methods of use thereof for delivery to cells
AU2020357178A1 (en) * 2019-10-04 2022-05-12 Gfb (Abc), Llc Biomarker-based treatment of focal segmental glomerulosclerosis and diabetic kidney disease
US12435330B2 (en) 2019-10-10 2025-10-07 The Broad Institute, Inc. Methods and compositions for prime editing RNA
TWI902715B (zh) 2019-10-30 2025-11-01 美商律幫治療股份有限公司 作為ｐａｒｐ７抑制劑的嗒酮
US12564595B2 (en) 2019-11-28 2026-03-03 Shionogi & Co., Ltd. Prophylactic and therapeutic pharmaceutical agent for HIV infectious diseases characterized by comprising combination of integrase inhibitor and anti-HIV agent
TW202146416A (zh) 2019-12-11 2021-12-16 德商拜耳廠股份有限公司 吡唑并三𠯤
CA3177481A1 (en) 2020-05-08 2021-11-11 David R. Liu Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence
BR112023001272A2 (pt) 2020-07-24 2023-04-04 Massachusetts Gen Hospital Partículas semelhantes a vírus aprimoradas e métodos de uso das mesmas para entrega às células
CA3193099A1 (en) 2020-09-24 2022-03-31 David R. Liu Prime editing guide rnas, compositions thereof, and methods of using the same
AU2022206476A1 (en) 2021-01-11 2023-07-20 President And Fellows Of Harvard College Prime editor variants, constructs, and methods for enhancing prime editing efficiency and precision
WO2023275230A1 (en) * 2021-07-01 2023-01-05 Janssen Pharmaceutica Nv 5-oxo-pyrido[2,3-d]pyridazin-6(5h)-yl acetamides
AU2022325166A1 (en) 2021-08-06 2024-02-08 President And Fellows Of Harvard College Improved prime editors and methods of use
US20240417719A1 (en) 2021-10-25 2024-12-19 The Broad Institute, Inc. Methods and compositions for editing a genome with prime editing and a recombinase
IL313146A (en) 2021-12-03 2024-07-01 Harvard College Self-assembling virus-like particles for delivery of prime editors and methods of making and using same
WO2023205687A1 (en) 2022-04-20 2023-10-26 The Broad Institute, Inc. Improved prime editing methods and compositions
WO2023240137A1 (en) 2022-06-08 2023-12-14 The Board Institute, Inc. Evolved cas14a1 variants, compositions, and methods of making and using same in genome editing
WO2024077267A1 (en) 2022-10-07 2024-04-11 The Broad Institute, Inc. Prime editing methods and compositions for treating triplet repeat disorders
WO2024108092A1 (en) 2022-11-17 2024-05-23 The Broad Institute, Inc. Prime editor delivery by aav
EP4662306A2 (en) 2023-02-09 2025-12-17 The Broad Institute Inc. Evolved recombinases for editing a genome in combination with prime editing
WO2024206125A1 (en) 2023-03-24 2024-10-03 The Broad Institute, Inc. Use of prime editing for treating sickle cell disease
US20250026759A1 (en) 2023-07-07 2025-01-23 Merck Sharp & Dohme Llc Tetrahydroquinazoline derivatives as selective cytotoxic agents
WO2025081042A1 (en) 2023-10-12 2025-04-17 Renagade Therapeutics Management Inc. Nickase-retron template-based precision editing system and methods of use
WO2025193566A1 (en) * 2024-03-15 2025-09-18 Merck Sharp & Dohme Llc N-oxide derivatives as selective cytotoxic agents

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5663169A (en) 1992-08-07 1997-09-02 Merck & Co., Inc. Benzoxazinones as inhibitors of HIV reverse transcriptase
CZ20003978A3 (cs) 1998-04-27 2001-09-12 Centre National De La Recherche Scientifique Deriváty 3-(amino- nebo aminoalkyl) pyridinonu a jejich použití
IT1305313B1 (it) 1998-07-17 2001-05-04 Colla Paolo 3,4 - diidro- 6- benzil-4-oxopirimidine sostituite e relativo processodi produzione e impiego nella terapia delle infezioni da hiv-1.
SE9904045D0 (sv) 1999-11-09 1999-11-09 Astra Ab Compounds
AU2001290912A1 (en) 2000-09-15 2002-03-26 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
EP1597237B1 (en) 2003-02-07 2016-07-27 Janssen Pharmaceutica NV Pyrimidine derivatives for the prevention of HIV infection
TW200423930A (en) 2003-02-18 2004-11-16 Hoffmann La Roche Non-nucleoside reverse transcriptase inhibitors
WO2004085406A1 (en) 2003-03-24 2004-10-07 F. Hoffmann-La Roche Ag Benzyl-pyridazinons as reverse transcriptase inhibitors
TW200505441A (en) 2003-03-24 2005-02-16 Hoffmann La Roche Non-nucleoside reverse transcriptase inhibitorsⅠ
CA2552584A1 (en) 2004-01-12 2005-08-04 Gilead Sciences, Inc. Pyrimidyl phosphonate antiviral compounds and methods of use
EP1730120A1 (en) 2004-03-23 2006-12-13 F.Hoffmann-La Roche Ag Non-nucleoside reverse transcriptase inhibitors
AU2005235692B2 (en) 2004-04-23 2011-11-10 F. Hoffmann-La Roche Ag Non-nucleoside reverse transcriptase inhibitors
US7166738B2 (en) 2004-04-23 2007-01-23 Roche Palo Alto Llc Non-nucleoside reverse transcriptase inhibitors
JP2008525419A (ja) 2004-12-22 2008-07-17 ファイザー・リミテッド Ｈｉｖ−１逆転写酵素の非ヌクレオシド阻害剤
AR057455A1 (es) 2005-07-22 2007-12-05 Merck & Co Inc Inhibidores de la transcriptasa reversa de vih y composicion farmaceutica
ES2320042T3 (es) 2005-10-19 2009-05-18 F. Hoffmann-La Roche Ag Inhibidores de transcriptasa reversa con nucleosidos de n-fenil fenilacetamida.
EP1940781A1 (en) 2005-10-19 2008-07-09 F.Hoffmann-La Roche Ag Phenyl-acetamide nnrt inhibitors
US7803940B2 (en) 2006-11-24 2010-09-28 Takeda Pharmaceutical Company Limited Heteromonocyclic compound or a salt thereof having strong antihypertensive action, insulin sensitizing activity and the like production thereof and use thereof for prophylaxis or treatment of cardiovascular diseases, metabolic diseases and/or central nervous system diseases
EA200970510A1 (ru) 2006-11-24 2009-12-30 Такеда Фармасьютикал Компани Лимитед Гетеромоноциклическое соединение и его применение
TW200831085A (en) 2006-12-13 2008-08-01 Merck & Co Inc Non-nucleoside reverse transcriptase inhibitors
CN101952274A (zh) 2007-11-20 2011-01-19 默沙东公司 非核苷逆转录酶抑制剂
EP2231621B1 (en) * 2008-01-08 2016-11-02 Merck Sharp & Dohme Corp. Process for preparing n-substituted hydroxypyrimidinone carboxamides
MX2012011379A (es) 2010-03-30 2012-11-30 Merck Canada Inc Inhibidores no nucleosidicos de la transcriptasa inversa.
WO2011126969A1 (en) 2010-04-08 2011-10-13 Merck Sharp & Dohme Corp. Prodrugs of an hiv reverse transcriptase inhibitor
JO3470B1 (ar) * 2012-10-08 2020-07-05 Merck Sharp & Dohme مشتقات 5- فينوكسي-3h-بيريميدين-4-أون واستخدامها كمثبطات ناسخ عكسي ل hiv
SI3125894T1 (sl) 2014-04-01 2020-12-31 Merck Sharp & Dohme Corp. Predzdravila inhibitorjev reverzne transkriptaze HIV

Also Published As

Publication number Publication date
JO3470B1 (ar) 2020-07-05
CY1122585T1 (el) 2021-01-27
US9469634B2 (en) 2016-10-18
PT3656384T (pt) 2022-03-22
MD20150047A2 (ro) 2015-08-31
NI201500048A (es) 2016-06-29
MD4625B1 (ro) 2019-04-30
DK3656384T3 (da) 2022-04-19
MY192716A (en) 2022-09-05
KR20150065186A (ko) 2015-06-12
HRP20171819T1 (hr) 2017-12-29
MD4625C1 (ro) 2019-11-30
HK1252786A1 (en) 2019-05-31
DK3295942T3 (da) 2020-02-10
HUE058903T2 (hu) 2022-09-28
US10189831B2 (en) 2019-01-29
PT3295942T (pt) 2020-02-18
EA033436B1 (ru) 2019-10-31
CA2887312A1 (en) 2014-04-17
GEP20186838B (en) 2018-04-10
EP2903977B1 (en) 2017-09-20
HUE037231T2 (hu) 2018-08-28
RS56543B1 (sr) 2018-02-28
EA201590674A1 (ru) 2016-02-29
JP2015533123A (ja) 2015-11-19
MX2015004448A (es) 2016-02-17
MX355040B (es) 2018-03-28
JP5877281B2 (ja) 2016-03-02
JP2016128470A (ja) 2016-07-14
HRP20200158T1 (hr) 2020-08-07
ZA201503143B (en) 2016-06-29
EP3295942B1 (en) 2019-11-20
AU2013329552A1 (en) 2015-04-16
CY1125202T1 (el) 2024-02-16
ME02918B (me) 2018-10-20
JP6097422B2 (ja) 2017-03-15
AR092876A1 (es) 2015-05-06
US20140100231A1 (en) 2014-04-10
SI3295942T1 (sl) 2020-03-31
TWI598343B (zh) 2017-09-11
HK1207369A1 (en) 2016-01-29
AU2013329552C1 (en) 2016-12-22
LT2903977T (lt) 2017-12-11
US20160145255A1 (en) 2016-05-26
CY1119655T1 (el) 2018-04-04
CO7350655A2 (es) 2015-08-10
ECSP15018618A (es) 2019-06-30
BR112015007742B8 (pt) 2021-03-23
EP3656384A1 (en) 2020-05-27
HUE048670T2 (hu) 2020-08-28
SG11201502620UA (en) 2015-05-28
PT2903977T (pt) 2017-11-14
PH12015500764B1 (en) 2019-04-05
ES2645638T3 (es) 2017-12-07
PL2903977T3 (pl) 2018-01-31
CA2887312C (en) 2017-02-28
IL238090B (en) 2019-02-28
TW201623256A (zh) 2016-07-01
TN2015000106A1 (en) 2016-06-29
US9718819B2 (en) 2017-08-01
LT3656384T (lt) 2022-05-10
GT201500088A (es) 2017-09-28
LT3295942T (lt) 2020-02-10
MA37959A2 (fr) 2017-12-29
EP2903977A1 (en) 2015-08-12
NO2903977T3 (pl) 2018-02-17
AP2015008355A0 (en) 2015-04-30
WO2014058747A1 (en) 2014-04-17
AU2013329552B2 (en) 2016-09-15
DOP2015000082A (es) 2015-08-16
ES2770774T3 (es) 2020-07-03
TWI538907B (zh) 2016-06-21
PL3295942T3 (pl) 2020-05-18
CR20150183A (es) 2015-08-10
EP3295942A1 (en) 2018-03-21
NZ706729A (en) 2018-09-28
RS63112B1 (sr) 2022-05-31
KR101696128B1 (ko) 2017-01-13
US20170349585A1 (en) 2017-12-07
CL2015000880A1 (es) 2015-08-28
PE20151787A1 (es) 2015-12-03
TW201420576A (zh) 2014-06-01
AU2013329552B8 (en) 2017-01-12
SI3656384T1 (sl) 2022-05-31
PH12015500764A1 (en) 2015-07-27
BR112015007742A2 (pt) 2017-08-08
DK2903977T3 (en) 2017-12-04
RS59863B1 (sr) 2020-03-31
CN104822670B (zh) 2018-01-12
ES2909190T3 (es) 2022-05-05
BR112015007742B1 (pt) 2021-01-19
CN104822670A (zh) 2015-08-05
SI2903977T1 (sl) 2017-12-29
UA114006C2 (xx) 2017-04-10
EP3656384B1 (en) 2022-02-23
HRP20220502T1 (hr) 2022-05-27

Similar Documents

Publication Publication Date Title
HUE048670T2 (hu) Kombinációk, amelyek tartalmaznak 5-fenoxi-3H-pirimidin-4-on származékokat és felhasználásuk HIV infekció profilaxisára vagy kezelésére
ZA201500921B (en) Alkylpyrimidine derivatives for the treatment of viral infections and further diaseases
IL253225A0 (en) Sulfamoyl-arylamides and their use as drugs to treat jaundice b
SI3019503T1 (sl) Policiklične karbamoilpiridonske spojine in njihova uporaba za zdravljenje HIV infekcij
SMT201700525T1 (it) Composti di carbamoilpiridone policiclici e loro uso per il trattamento di infezioni da hiv
ZA201601344B (en) Methods and compositions for rna-guided treatment of hiv infection
ZA201405820B (en) Piperidino-pyrimidine derivatives for the treatment of viral infections
ZA201502238B (en) Acylaminopyrimidine derivatives for the treatment of viral infections and further diseases
ZA201407866B (en) Composition for the prevention and treatment of viral infections caused by retroviruses
AU2012900286A0 (en) "Methods of treatment or prophylaxis"
AU2012902449A0 (en) Novel animal infection treatment and prophylaxis